These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

245 related items for PubMed ID: 26452431

  • 1. Successful treatment with alectinib after crizotinib-induced interstitial lung disease.
    Chino H, Sekine A, Kitamura H, Kato T, Ogura T.
    Lung Cancer; 2015 Dec; 90(3):610-3. PubMed ID: 26452431
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib.
    Taima K, Tanaka H, Tanaka Y, Itoga M, Takanashi S, Tasaka S.
    Intern Med; 2017 Sep 01; 56(17):2321-2324. PubMed ID: 28794366
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
    Shirasawa M, Kubotaa M, Harada S, Niwa H, Kusuhara S, Kasajima M, Hiyoshi Y, Ishihara M, Igawa S, Masuda N.
    Lung Cancer; 2016 Sep 01; 99():66-8. PubMed ID: 27565916
    [Abstract] [Full Text] [Related]

  • 12. Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
    Shaw AT, Gandhi L, Gadgeel S, Riely GJ, Cetnar J, West H, Camidge DR, Socinski MA, Chiappori A, Mekhail T, Chao BH, Borghaei H, Gold KA, Zeaiter A, Bordogna W, Balas B, Puig O, Henschel V, Ou SI, study investigators.
    Lancet Oncol; 2016 Feb 01; 17(2):234-242. PubMed ID: 26708155
    [Abstract] [Full Text] [Related]

  • 13. Alectinib surpasses crizotinib for untreated ALK-positive NSCLC.
    Gilbert JA.
    Lancet Oncol; 2017 Jul 01; 18(7):e377. PubMed ID: 28625556
    [No Abstract] [Full Text] [Related]

  • 14. Successful treatment of crizotinib-induced dysgeusia by switching to alectinib in ALK-positive non-small cell lung cancer.
    Koizumi T, Fukushima T, Tatai T, Kobayashi T, Sekiguchi N, Sakamoto A, Sasaki S.
    Lung Cancer; 2015 Apr 01; 88(1):112-3. PubMed ID: 25678258
    [Abstract] [Full Text] [Related]

  • 15. Alectinib for ALK-positive non-small-cell lung cancer.
    Rossi A.
    Expert Rev Clin Pharmacol; 2016 Aug 01; 9(8):1005-13. PubMed ID: 27232673
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Transformation to small-cell lung cancer as a mechanism of acquired resistance to crizotinib and alectinib.
    Miyamoto S, Ikushima S, Ono R, Awano N, Kondo K, Furuhata Y, Fukumoto K, Kumasaka T.
    Jpn J Clin Oncol; 2016 Feb 01; 46(2):170-3. PubMed ID: 26613679
    [Abstract] [Full Text] [Related]

  • 18. Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis.
    Asao T, Fujiwara Y, Itahashi K, Kitahara S, Goto Y, Horinouchi H, Kanda S, Nokihara H, Yamamoto N, Takahashi K, Ohe Y.
    Clin Lung Cancer; 2017 Jul 01; 18(4):e251-e258. PubMed ID: 28065466
    [Abstract] [Full Text] [Related]

  • 19. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease.
    Tachihara M, Kobayashi K, Ishikawa Y, Hori S, Tamura D, Otera H, Funada Y, Nishimura Y.
    Jpn J Clin Oncol; 2014 Aug 01; 44(8):762-4. PubMed ID: 24872405
    [Abstract] [Full Text] [Related]

  • 20. Crizotinib Associated with Ground-Glass Opacity Predominant Pattern Interstitial Lung Disease: A Retrospective Observational Cohort Study with a Systematic Literature Review.
    Créquit P, Wislez M, Fleury Feith J, Rozensztajn N, Jabot L, Friard S, Lavole A, Gounant V, Fillon J, Antoine M, Cadranel J.
    J Thorac Oncol; 2015 Aug 01; 10(8):1148-55. PubMed ID: 26200268
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.